News for TPTX Stock

Bristol Myers Squibb and Turning Point Therapeutics Announce Expiration of HSR Act Waiting Period and Clearance from Federal Cartel Office of Germany Related to Pending Acquisition of Turning Point Therapeutics Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational Updates Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLC Bristol Myers Squibb Reports Second Quarter Financial Results for 2022 Bristol Myers Squibb Announces Extension of Turning Point Tender Offer Turning Point Therapeutics and MD Anderson Announce Strategic Alliance to Advance Precision Cancer Therapies Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company Turning Point Therapeutics to Participate in Upcoming Investor Conferences Turning Point Therapeutics Announces Appointment of Steve Sabus as Chief Commercial Officer Turning Point Therapeutics Reports First-Quarter 2022 Financial Results, Provides Operational Updates Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy Turning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova Medicines Turning Point Therapeutics and Zai Lab Announce Topline Analysis in China Subpopulation for Repotrectinib in ROS1-Positive NSCLC Cohorts Within Global Phase 1/2 TRIDENT-1 Study Turning Point Therapeutics Announces Positive Topline Data by Blinded Independent Central Review for Repotrectinib Across All ROS1-Positive NSCLC Cohorts of Phase 1/2 TRIDENT-1 Study Turning Point Therapeutics Announces Appointment of Brian Sun, M.S., J.D., as Incoming General Counsel Turning Point Therapeutics Announces Achievement of Enrollment Goal for TRIDENT-1 NTRK-Positive TKI-Pretreated Advanced Solid Tumor Patients and Plans for Pre-NDA Meeting for This Patient Population Turning Point Therapeutics to Participate in Upcoming Investor Conferences Turning Point Therapeutics to Participate in 42nd Annual Cowen Healthcare Conference - Update Turning Point Therapeutics to Participate in 42nd Annual Cowen Healthcare Conference Turning Point Therapeutics Reports Fourth-Quarter and Full Year 2021 Financial Results, Provides Operational Updates Turning Point Therapeutics to Participate in Upcoming Investor Conferences Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Combination of Elzovantinib and Aumolertinib in EGFR Mutant Met-Amplified Non-Small Cell Lung Cancer Turning Point Therapeutics Provides Updates and Anticipated 2022 Clinical and Discovery Pipeline Milestones Turning Point Therapeutics Provides Regulatory Updates Turning Point Therapeutics to Participate in Upcoming Investor Conferences Turning Point Therapeutics Reports Third-Quarter Financial Results, Provides Operational Updates Turning Point Therapeutics Announces Appointment of Adam Levy as Senior Vice President of Investor Relations Turning Point Therapeutics to Host Third Quarter 2021 Conference Call Turning Point Therapeutics Presents Early Clinical Data for Repotrectinib From Care Study in Pediatric and Young Adult Patients at SIOP 2021 Virtual Congress Turning Point Therapeutics and EQRx Announce Clinical Collaboration to Evaluate Elzovantinib in Combination with Aumolertinib in Patients with EGFR Mutant Met-Amplified Advanced Non-Small Cell Lung Cancer Turning Point Therapeutics to Present Early Clinical Data for Repotrectinib From the CARE Study in Pediatric and Young Adult Patients at SIOP 2021 Virtual Congress Turning Point Therapeutics Presents TRIDENT-1 Study Clinical Data for Repotrectinib in NTRK+ Advanced Solid Tumors in Plenary Session at 2021 AACR-NCI-EORTC Conference Turning Point Therapeutics Presents Updated Preliminary Clinical Data for Repotrectinib and Elzovantinib (TPX-0022) at 2021 AACR-NCI-EORTC Conference and Provides Regulatory Updates Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with NTRK-Positive, TKI-Pretreated Advanced Solid Tumors Turning Point Therapeutics Announces Additional Details for Three Data Presentations at the 2021 AACR-NCI-EORTC Conference Turning Point Therapeutics Announces Early Clinical Data for Repotrectinib in NTRK Fusion-Positive Advanced Solid Tumors Selected for Late-Breaker Plenary Presentation at 2021 AACR-NCI-EORTC Conference Turning Point Therapeutics to Participate In Upcoming Investor Conferences Turning Point Therapeutics Initiates TRIDENT-2 Clinical Study Investigating Repotrectinib-Trametinib Combination in KRAS G12D Mutated Advanced Solid Tumors Turning Point Therapeutics Granted Sixth Regulatory Designation for Repotrectinib Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational Updates Turning Point Therapeutics to Host Second Quarter 2021 Conference Call Turning Point Therapeutics Appoints Paolo Tombesi as Executive Vice President and Chief Financial Officer Turning Point Therapeutics Granted FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer Turning Point Therapeutics to Participate in Goldman Sachs 42nd Annual Healthcare Conference Turning Point Therapeutics Names Former Celgene Chairman and CEO, Mark Alles, to Chair Its Board of Directors Turning Point Therapeutics Names Kumar Srinivasan as Executive Vice President, Chief Business Officer Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Operational Updates Turning Point Therapeutics to Host First Quarter 2021 Conference Call Turning Point Therapeutics Initiates Global Phase 1/2 Forge-1 Clinical Study of TPX-0131, a Next-Generation ALK Inhibitor Turning Point Therapeutics Announces New Preclinical Data for Three Drug Candidates Turning Point Therapeutics Announces Initial Clinical Data From Phase 1/2 SWORD-1 Study of RET Inhibitor TPX-0046 Turning Point Therapeutics Announces Board Changes Turning Point Therapeutics to Present New Preclinical Data For Three Drug Candidates at American Association For Cancer Research Annual Meeting Turning Point Therapeutics to Participate in Upcoming Investor Conferences Turning Point Therapeutics Reports Fourth-Quarter and Full-Year Financial Results, Provides Operational Updates Turning Point Therapeutics to Host Fourth Quarter and Full-Year 2020 Conference Call Turning Point Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days Turning Point Therapeutics Reports Updated Interim Data From Registrational Phase 2 Trident-1 Study of Repotrectinib in Patients With ROS1-Positive TKI-Naïve Non-Small Cell Lung Cancer Turning Point Therapeutics Announces 2021 Milestone Targets Turning Point and Zai Lab Broaden Collaboration Turning Point Therapeutics Granted FDA Breakthrough Therapy Designation for Repotrectinib Treatment in Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer Who Have Not Been Treated with a ROS1 Tyrosine Kinase Inhibitor Turning Point Therapeutics Reports Third-Quarter Financial Results, Provides Operational Updates Turning Point Therapeutics to Participate in Jefferies Virtual London Healthcare Conference Turning Point Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock Turning Point Therapeutics Announces Pricing of $400 Million Public Offering of Common Stock Turning Point Therapeutics Announces Commencement of Public Offering of Common Stock Turning Point Therapeutics Presents Initial Clinical Data From Phase 1 SHIELD-1 Study of Novel MET/SRC/CSF1R Inhibitor TPX-0022 at 2020 EORTC-NCI-AACR Symposium Turning Point Therapeutics to Host Conference Call to Discuss Presentations at 2020 EORTC-NCI-AACR Virtual Symposium Turning Point Therapeutics Announces Abstract For TRIDENT-1 Clinical Study of Repotrectinib Accepted For Presentation at World Conference on Lung Cancer Turning Point Therapeutics Announces Early Clinical Data For Novel MET Inhibitor TPX-0022 Selected For Late-Breaker Oral Presentation at 32nd EORTC-NCI-AACR Symposium Turning Point Therapeutics to Participate in Upcoming Virtual Investor Conference Turning Point Therapeutics to Participate in H.C. Wainwright Precision Oncology Investor Conference Turning Point Therapeutics Announces Scientific Advisory Board Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational Updates Turning Point Therapeutics Names Andrew Partridge As Executive Vice President and Chief Commercial Officer Turning Point Therapeutics’ Lead Drug Candidate Repotrectinib Increases Effectiveness of KRAS-G12C and MEK Inhibitors in Preclincal KRAS Cancer Models Turning Point Therapeutics Presents Preclinical Data For Novel RET Inhibitor Candidate, TPX-0046 Turning Point Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock Turning Point Therapeutics Reports First-Quarter Financial Results, Provides Update on Operations and COVID-19 Response Turning Point Therapeutics Names Heather Adams as Vice President of Human Resources Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement For Repotrectinib in Greater China Turning Point Therapeutics to Participate in Goldman Sachs 41st Annual Global Healthcare Conference Webcast Turning Point Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock Turning Point Therapeutics Announces Commencement of Public Offering of Common Stock Turning Point Therapeutics to Host First Quarter Conference Call